QLT

Vancouver, Canada Founded: 1981 • Age: 45 yrs
Biopharma specializing in opthalmology
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About QLT

QLT is a company based in Vancouver (Canada) founded in 1981. QLT has completed 1 acquisition, including Aegerion. QLT operates in a competitive market with competitors including GSK, Avidity Biosciences, Kriya Therapeutics, Annexon and Sutro Biopharma, among others.

  • Headquarter Vancouver, Canada
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of QLT

Premium access

Detailed funding history for QLT

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by QLT

QLT has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Aegerion.

Investments
Premium access

Investment portfolio details for QLT

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
Locked Locked 2005 Locked
Premium access

Complete acquisition details for QLT

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - QLT

Premium access

Detailed financials for QLT

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Qlt Comparisons

QLT Primary company
Description
Biopharma specializing in opthalmology
Location
Vancouver, Canada
Founded Year
1981
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for QLT

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of QLT

QLT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Kriya Therapeutics, Annexon and Sutro Biopharma, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of pharmaceuticals and vaccines for various therapeutic areas
Locked Locked Locked
Antibody-siRNA complexes are developed for cancer treatment.
Locked Locked Locked
Developer of therapeutic solutions for the treatment of diabetes
Locked Locked Locked
Developer of antibodies to treat complement-mediated neurodegenerative diseases
Locked Locked Locked
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Locked Locked Locked
Yeast cells are genetically engineered to produce medicinal products.
Premium access

Detailed competitors of QLT

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Qlt

Premium access

Complete news archive for QLT

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about QLT

QLT was founded in 1981.

QLT is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.

QLT is biopharmaceutical company that ngages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.

QLT's top competitors include Sutro Biopharma, Synthego and Annexon.

QLT has made 1 acquisition, including Aegerion.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available